With vaccine revenue crumbling and layoffs in full swing, is Moderna’s slimmed-down strategy a smart move or a red flag for ...

The U.S. health secretary ordered an end to new mRNA development efforts just after UTMB published new research showing its ...

Canadian doctors and scientists also say Kennedy’s false claims and overall disinformation will cause ‘confidence crisis’ ...

Unlike other vaccines, mRNA vaccines can be made very quickly. They can also be easily modified to fight new viruses and ...

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...

The Trump Administration said this week it is pulling half a billion dollars from U.S. government-funded research projects to create new mRNA vaccines. Experts say this could potentially impact mRNA ...

The U.S. health department is canceling or scaling back 22 BARDA-backed mRNA projects worth nearly $500 million, shifting ...

In a report released yesterday, Cory Kasimov from Evercore ISI maintained a Hold rating on Moderna, with a price target of $32.00. The company’s shares closed yesterday at $27.64. Take advantage of ...

Despite a net loss, Moderna Inc (MRNA) showcases resilience with significant cost cuts, new FDA approvals, and a robust cash ...

An official overseeing implementation of the Make America Healthy Again agenda at the Department of Health and Human Services ...

Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, ...

Messenger RNA vaccines, or mRNA, differ from traditional ones. Instead of growing a virus and weakening it to allow the body to engage its natural defenses, mRNA vaccines use pieces of genetic code to ...